Recent QLGN News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/22/2024 08:41:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:06:05 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:01:09 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/09/2024 07:58:55 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/07/2024 09:28:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:10:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 09:00:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 09:06:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2024 10:15:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 09:25:27 PM
- Lifecore Biomedical Announces Cooperation Agreement with 22NW • GlobeNewswire Inc. • 07/01/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:00:18 PM
- Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination • GlobeNewswire Inc. • 05/30/2024 08:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/14/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 05/04/2024 12:59:19 AM
- Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/10/2024 12:00:00 PM
- Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:10:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:30:40 PM
- Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 • GlobeNewswire Inc. • 11/14/2023 09:30:00 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM